Ovarian Diseases clinical trials

The registry lists 45 studies for Ovarian Diseases across more than 10 countries. 6 are recruiting or about to start. 9 of them are mainly about Ovarian Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-29. Counting its 12 narrower conditions too, such as Ovarian Neoplasms: 5,132 studies, 1,107 open.

Get an email when these change. Save the Ovarian Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 20
Status unknown: 10
Terminated: 6
Recruiting: 4
Not yet recruiting: 2
Active, not recruiting: 1

Phase

Phase 2: 17
Phase 1: 8
Phase 3: 1
Early Phase 1: 1

Where

United States: 14
Germany: 6
United Kingdom: 5
China: 5
Belgium: 4
France: 4

Who runs them

KU Leuven (2) · Xiaoxiang Chen (2) · Kanuni Sultan Suleyman Training and Research Hospital (2) · AGO Study Group (2) · Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona (2) · Astellas Pharma Inc (2) · University of Colorado, Denver (1) · Fujian Cancer Hospital (1)

What is being tested here

Drugs under test in Ovarian Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Bevacizumab	1	0	2
Adebrelimab	1	0	1
Fluzoparib	1	0	1
Pembrolizumab	1	0	1
Lenvatinib	1	0	1
Paclitaxel	0	1	3
Anlotinib	0	0	2
Carboplatin	0	1	2
Niraparib	0	0	2
Entinostat	0	0	1

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · PARP inhibitors 1 open · Antimitotic agents 3

Coming up

0phase 3 studies under way

2studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 2

Dec 2026A Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gynecological Day Surgery · Second Affiliated Hospital of Wenzhou Medical University
Aug 2027Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer · Massachusetts General Hospital

Who these studies take

Of the 4 Ovarian Diseases studies recruiting now, 3 (75%) set no upper age limit and 1 (25%) stop at 75 or younger. 0 (0%) take children under 18. 4 (100%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 4
Age	Women	Men
10	0 (0%)	0 (0%)
18	3 (75%)	0 (0%)
30	4 (100%)	0 (0%)
40	4 (100%)	0 (0%)
50	4 (100%)	0 (0%)
65	4 (100%)	0 (0%)
75	3 (75%)	0 (0%)
85	3 (75%)	0 (0%)

Across all 45 studies, recruiting or not: 27% stop at 75 or younger and 20% at 65; 11% take children; 91% are for women only and 0% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 14, 2026.

Stopped1

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian CancerTerminatedOct 29, 2026NCT05617755

Studies

Recruiting first, then most recently updated. Showing 45 of 45. search them.